CN1176602C - Health food capable of increasing bone density and delaying senility and its production process - Google Patents
Health food capable of increasing bone density and delaying senility and its production process Download PDFInfo
- Publication number
- CN1176602C CN1176602C CNB021511470A CN02151147A CN1176602C CN 1176602 C CN1176602 C CN 1176602C CN B021511470 A CNB021511470 A CN B021511470A CN 02151147 A CN02151147 A CN 02151147A CN 1176602 C CN1176602 C CN 1176602C
- Authority
- CN
- China
- Prior art keywords
- extraction
- health food
- bone density
- health
- angelicae sinensis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000037182 bone density Effects 0.000 title claims abstract description 34
- 235000013402 health food Nutrition 0.000 title claims description 23
- 238000004519 manufacturing process Methods 0.000 title claims description 10
- 230000001965 increasing effect Effects 0.000 title abstract description 6
- 239000000843 powder Substances 0.000 claims abstract description 23
- 238000000605 extraction Methods 0.000 claims abstract description 19
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 14
- 244000068988 Glycine max Species 0.000 claims abstract description 14
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 11
- 229920002472 Starch Polymers 0.000 claims abstract description 11
- 239000004227 calcium gluconate Substances 0.000 claims abstract description 11
- 229960004494 calcium gluconate Drugs 0.000 claims abstract description 11
- 235000013927 calcium gluconate Nutrition 0.000 claims abstract description 11
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 11
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 11
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 11
- 239000011734 sodium Substances 0.000 claims abstract description 11
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 11
- 235000019698 starch Nutrition 0.000 claims abstract description 11
- 239000008107 starch Substances 0.000 claims abstract description 11
- 239000000284 extract Substances 0.000 claims abstract description 10
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims abstract description 10
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000008696 isoflavones Nutrition 0.000 claims abstract description 10
- 241001061264 Astragalus Species 0.000 claims abstract description 7
- 235000006533 astragalus Nutrition 0.000 claims abstract description 7
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims abstract description 7
- 239000008187 granular material Substances 0.000 claims abstract description 7
- 238000002481 ethanol extraction Methods 0.000 claims abstract description 4
- 238000003809 water extraction Methods 0.000 claims abstract description 4
- 239000000047 product Substances 0.000 claims description 23
- 210000000582 semen Anatomy 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000005303 weighing Methods 0.000 claims description 13
- 239000009636 Huang Qi Substances 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 230000003712 anti-aging effect Effects 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 5
- 239000007888 film coating Substances 0.000 claims description 5
- 238000009501 film coating Methods 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- 210000004233 talus Anatomy 0.000 claims description 5
- 244000061520 Angelica archangelica Species 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000007670 refining Methods 0.000 claims description 3
- 238000002474 experimental method Methods 0.000 abstract description 12
- 241001465754 Metazoa Species 0.000 abstract description 11
- 238000002360 preparation method Methods 0.000 abstract description 10
- 235000013305 food Nutrition 0.000 abstract description 6
- 241000213006 Angelica dahurica Species 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 5
- 238000012545 processing Methods 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 239000011248 coating agent Substances 0.000 abstract description 2
- 238000000576 coating method Methods 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 abstract 2
- 241000893536 Epimedium Species 0.000 abstract 2
- 240000000249 Morus alba Species 0.000 abstract 2
- 235000008708 Morus alba Nutrition 0.000 abstract 2
- 235000018905 epimedium Nutrition 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 238000002156 mixing Methods 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 28
- 239000000523 sample Substances 0.000 description 28
- 230000000694 effects Effects 0.000 description 25
- 210000000689 upper leg Anatomy 0.000 description 21
- 210000000988 bone and bone Anatomy 0.000 description 16
- 210000003734 kidney Anatomy 0.000 description 15
- 230000037396 body weight Effects 0.000 description 14
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 11
- 229960005069 calcium Drugs 0.000 description 11
- 239000011575 calcium Substances 0.000 description 11
- 229910052791 calcium Inorganic materials 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 239000000306 component Substances 0.000 description 9
- 102000019197 Superoxide Dismutase Human genes 0.000 description 8
- 108010012715 Superoxide dismutase Proteins 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 238000005189 flocculation Methods 0.000 description 7
- 230000016615 flocculation Effects 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 239000013049 sediment Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000032683 aging Effects 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- -1 lipid peroxide Chemical class 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 208000001132 Osteoporosis Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- 235000019219 chocolate Nutrition 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 230000001076 estrogenic effect Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
- 231100000111 LD50 Toxicity 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 235000003969 glutathione Nutrition 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000000528 statistical test Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 2
- 241000288673 Chiroptera Species 0.000 description 2
- 241000255601 Drosophila melanogaster Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- MRELNEQAGSRDBK-UHFFFAOYSA-N lanthanum(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[La+3].[La+3] MRELNEQAGSRDBK-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 238000004137 mechanical activation Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 231100000628 reference dose Toxicity 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241000045500 Diseae Species 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 229930187719 Soyasaponin Natural products 0.000 description 1
- 206010041611 Spine malformation Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960004343 alendronic acid Drugs 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000012805 animal sample Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000008394 flocculating agent Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 102000036124 hormone binding proteins Human genes 0.000 description 1
- 108091011044 hormone binding proteins Proteins 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 description 1
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000009645 skeletal growth Effects 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/05—Mashed or comminuted pulses or legumes; Products made therefrom
- A23L11/07—Soya beans, e.g. oil-extracted soya bean flakes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Agronomy & Crop Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a health-care food for increasing bone density and delaying senility, which is made from soy beans, epimedium herb, milkvetch root, Chinese angelica and mulberry which are used as active ingredients as well as calcium gluconate, sodium carboxymethyl starch and microcrystalline cellulose which are used as auxiliary materials. A preparation method of the health-care food comprises the following steps: extracting Chinese angelica oil through a supercritical CO2 extraction process; extracting extracts of soy bean isoflavone from the soy beans through ethanol extraction; preparing spray-dry powder from the epimedium herb, the milkvetch root, the mulberry and Chinese angelica powder obtained after oil extraction through water extraction and processing; uniformly mixing the Chinese angelica oil, the extracts and the spray-dry powder; adding the calcium gluconate, the sodium carboxymethyl starch and the microcrystalline cellulose later so as to obtain granules, and then processing through preforming and coating so as to obtain tablets as finished products. Animal experiments show that the food has the functions of increasing the bone density and delaying the senility. Modern pharmacological and clinical research shows that products of the present invention have the health-care functions of increasing the bone density and delaying the senility and are suitable for long-term administration as health-care foods.
Description
Technical field
The present invention relates to a kind of bone density improving and anti-aging health food, be about a kind of be the main bone density improving of making and anti-aging health food and preparation method thereof with the medicine and food raw materials.
Background technology
Aging is body tissue structural change and the hypokinetic a kind of organic growth process that occurs along with the increase at age.Be accompanied by human senility, the body bone metabolism also can get muddled, balance between osteoblast and osteoclast effect is broken, bone resorption causes that greater than bone formation the bone amount reduces, and bone density descends, finally cause osteoporosis, lumbar and back pain, spine malformation can be arranged, and very easily fracture, have a strong impact on people's quality of life.Bone density decline and osteoporosis are particularly serious in postclimacteric elderly woman, and prevalence is up to about 50%.Good Therapeutic Method is not arranged in the market as yet.Someone uses controversies in hormone replacement in the elderly to prevent and treats the decline of bone density, prevents osteoporotic generation.But, multinomial studies show that, the utilization controversies in hormone replacement in the elderly can obviously increase the incidence rate of carcinoma of endometrium and breast carcinoma, thereby is not to be a kind of very good Therapeutic Method.Therefore develop bone density improving and anti-aging health food is very necessary.
Summary of the invention
The present invention provides a kind of bone density improving and anti-aging health food and preparation method thereof.
Product of the present invention is the health food according to the theoretical exploitation of traditional Chinese medicine theory and health care, is with Semen sojae atricolor, Herba Epimedii, the Radix Astragali, Radix Angelicae Sinensis, Fructus Mori is an effective ingredient, join again with the adjuvant calcium gluconate, carboxymethyl starch sodium and microcrystalline Cellulose are formed.
The component of health food of the present invention and weight portion content thereof are as follows:
| Component | Semen sojae atricolor Herba Epimedii astragalus, angelica Fructus Mori calcium gluconate carboxymethyl starch sodium microcrystalline Cellulose |
| Weight portion | 10-40 3-10 3-10 3-10 1-10 0.3-3 0.1-3 0.1-3 |
The optimum content of health food component of the present invention is
| Component | Semen sojae atricolor Herba Epimedii astragalus, angelica Fructus Mori calcium gluconate carboxymethyl starch sodium microcrystalline Cellulose |
| Weight portion | 20 10 10 5 5 0.4 0.3 0.3 |
Semen sojae atricolor in the prescription, Herba Epimedii, the Radix Astragali, Radix Angelicae Sinensis and Fructus Mori show to have the function of certain bone density improving and slow down aging through modern pharmacology and clinical research, suit to take for a long time as health food.Below set forth its compound basis respectively according to health care classification.
The compound basis of bone density improving effect:
1) contain abundant isoflavonoid in the extract of legume soybean, to bone density improving, improving osteoporosis has good action (Picherit C et al.J Nutri, 2000,130 (7): 1675～1681).Soybean isoflavone is typical phytoestrogen, and has dual regulation, when promptly body inner estrogen level is low, can increase estrogenic biological effect by increasing the number and the affinity of estrogen receptor, presents estrogen-like effects; When body inner estrogen level is high, can regulate intravital sex hormone binding protein again, weaken estrogenic biological effect, show the effect of estrogen antagonist sample.Therefore, soybean isoflavone can be regulated the disorder of body inner estrogen level well, and does not have the inevitably side effect of hormone medicine institute.
2) the modern pharmacology experimentation shows, the Herba Epimedii extracting solution exists " benefit bone " effect, the activity that can suppress osteoclast, simultaneously can promote osteoblastic function again, calcified bone is formed increases bone density improving, there is good prevention effect (high plain strong etc. to osteoporosis, CHINA JOURNAL OF CHINESE MATERIA MEDICA, 1999,24 (4): 249～251).
3) Radix Astragali can make mice obviously prolong rutting period, and prompting has the promotion estrogen-like effects; Astragalus polysaccharides can directly or indirectly act on osteoblast, osteoporosis (Wang Yongjun etc., Chinese orthopedics and traumatology of Chinese medicine magazine, 1999,7 (6): 1～4).
In sum, this prescription should have the health care of bone density improving.
The compound basis of delaying senility function:
1) soyasaponins in the soybean extract is by regulating metabolism, increase the content of superoxide dismutase (SOD), reduce lipid peroxide (LPO) concentration, thereby reduce or elimination radical pair cells injury, effect (Zheng Gaoli etc. with the oxidation of lipotropism matter and reduction lipid oxide, the Zhejiang Medical university journal, 1997,36 (5): 196～199).
2) Herba Epimedii has function in delaying senility, the activity of SOD, glutathion peroxidase (GSH-PX) in aged animal blood and the tissue be can obviously improve, mouse cardiac muscle lipofuscin content (Ceng Nan etc., CHINA JOURNAL OF CHINESE MATERIA MEDICA reduced, 1997,22 (1): 46～48).
3) Radix Astragali contains polysaccharide, monosaccharide, flavone compound, alkaloid, folic acid, several amino acids, vitamin, bitter principle, and 14 kinds of trace element that needed by human body is wanted such as selenium, zinc, ferrum.Can reduce the collagen content of old rat aorta and lung, prolong the life-span of cell in growth in vitro; Can also make that superoxide dismutase activity obviously increases in the whole blood, lipid peroxide content obviously reduces, and oxygen-derived free radicals is had very strong elimination effect (Lei Hong, Chinese herbal medicine, 1992,23 (9): 469～473).
4) effective ingredient in the Radix Angelicae Sinensis can be by eliminating free radical, inhibited oxidation reaction and radical reaction, and with the infringement of multiple mechanism antagonism radical pair tissue such as biological film phospholipid join protection membrane lipid.
5) contain multivitamin and mineral in the Fructus Mori, have good health-care effect.Modern pharmacological research finds that also Fructus Mori can promote T lymphocyte maturation, and old and feeble T lymphocyte function is restored.
In sum, this prescription should have the health care of slow down aging.
Motherland's medical science thinks, old and feeble development has confidential relation with the variation of kidney, and skeletal growth, healthy and strong and regeneration to fill Sheng with the vital essence of kidney be inseparable.Kidney storing essence, the smart marrow of giving birth to, the marrow bone growth promoting is so " closing of bone person kidney " is also." ancient Chinese medical classics essential ideas ": " osteopathia then takes place the vital essence scarcity of kidney ".The kidney essense kidney qi is enriched, and then bone marrow biochemistry is active, and skeleton is firm, and is strong strong; If deficiency of kidney-QI, deficiency of kidney-essence, then bone marrow lacks the source, and skeleton loses supports.As seen, the variation of kidney is one of major reason of human senility, directly affects the whether firm of body skeleton.Therefore, nurse one's health the kidney the congenital foundation early, will be to strong skeleton, slow down aging has important function, and the conditioning emphasis by adjusting human body yin-yang balancing, is mended the marrow bone strengthening when being kidney tonifying, essence replenishing, benefiting QI and nourishing blood, and bone strengthening prolongs and declines.
Product of the present invention is according to the tcm treatment according to syndrome differentiation theory, in line with prevention of diseae and the basic guideline prescription of giving consideration to both the incidental and fundamental, and Semen sojae atricolor in the side, nature and flavor are sweet flat, go into the spleen kidney channel." book on Chinese herbal medicine converges and usurps ": " damp flesh benefit bone "; Herba Epimedii, suffering, sweet, temperature is returned the Liver and kidney warp.Claim the effect that it has " hard muscles and bones is mended the waist knee joint, heart tonifying power " in the Compendium of Material Medica, the two is shared and be monarch drug, and temperature compensation kidney the yang aspect of yang gas fills bone and adds marrow.More use the Radix Astragali and Radix Angelicae Sinensis compatibility, strengthening the spleen stomach the foundation of acquired constitution, the prosperous blood of gas is given birth to, and QI and blood is full.Fructus Mori, sweet in flavor and cold in property, function nourishing YIN and benefiting blood, more anti-overheated anxiety.Five tastes compatibility amounts to the temperature compensation kidney essense, the effect of nourishing YIN and benefiting blood.
It is to be purpose with the health body-building that recipe ingredient of the present invention is considered, so dosage is unsuitable excessive, and the dosage of reference treatment senile disease and defying age body-building adopts to be lower than medicine therapeutic dose commonly used, referring to table 1.The Herba Epimedii and the Radix Astragali are all got the minimum flow of therapeutic dose commonly used in the component of the present invention, to guarantee the performance of its effect.
Table 1
| Treatment senile disease reference dose | Defying age body-building reference dose | Optimal dose of the present invention | |
| Semen sojae atricolor | 5～30g/ day | 20g/ day | |
| Herba Epimedii | 10～12g/ day | 10g/ day | |
| The Radix Astragali | 10～15g/ day | 3～10g/ day | 10g/ day |
| Radix Angelicae Sinensis | 10～15g/ day | 3～6g/ day | 5g/ day |
| Fructus Mori | 10～15g/ day | 5g/ day |
Calcium gluconate in the prescription, carboxymethyl starch sodium and microcrystalline Cellulose are the required adjuvant of press sheet formulation, all meet national standard.
Above-mentioned each component is made the preparation method of health food of the present invention, comprises following each step:
1, take by weighing Radix Angelicae Sinensis, grinding and sieving 20 orders, the Chinese Angelica Root that obtains adopts supercritical CO
2Extraction process is extracted: powder is put into supercritical CO
2Extraction pot, extraction pressure is 5-20MPa, extracting temperature is 20-60 ℃; In knockout drum, separate then Radix Angelicae Sinensis oil, standby, separating pressure is 1-1.5MPa, separation temperature is 15-20 ℃; Liquid CO
2Flow is 20-40Nm
3/ h recycles on stream and extracts, and extraction time is 1-3 hour, takes out the Radix Angelicae Sinensis powder carry behind the oil from extraction pot, and is standby;
2, take by weighing Semen sojae atricolor, grinding and sieving 20 orders are used 80% ethanol extraction after the powdered soybean defat that obtains, and extracting solution concentrates in 60-80 ℃, and is refining by 90-95% ethanol again, drying, purity is 40% soybean isoflavone, standby;
3, take by weighing Herba Epimedii, the Radix Astragali and Fructus Mori, with the above-mentioned standby Radix Angelicae Sinensis powder of carrying behind the oil, water with 10-12 times (weight ratio) extracts, be heated to the 95-98 ℃ of Asia state that boils, dynamic circulation water extraction 1-3 hour, extracting solution filters with 60 mesh filter screens, filtrate is vacuum concentration under 50-80 ℃ and vacuum 0.04-0.09MPa, reaches 1.03-1.04 (60-65 ℃) to relative density, adds the chitosan that concentration is 200-500ppm again, flocculation sediment 0.5-1 hour, with 200 order micropore fine filtrations, fine straining liquid is vacuum concentration under 50-80 ℃ and vacuum 0.04-0.09MPa with flocculation sediment liquid, reaches 1.08-1.10 (60-65 ℃) to the concentrated solution relative density.With the gained concentrated solution, spray drying gets spray powder;
4, Radix Angelicae Sinensis oil and the soybean isoflavone that spray powder and said extracted are got fully mixes, and gets mixed powder, adds calcium gluconate again, carboxymethyl starch sodium and microcrystalline Cellulose, and stirring is mixed, and 80 orders that sieve are granulated, and drying gets granule;
5, with the granule tabletting, film coating, tablet gets product.
Control of product quality of the present invention adopts advanced high-efficient liquid phase chromatogram technology, its functional component is monitored quantitative analysis, as isoflavone (in genistein) 〉=2300mg/100g finished product, icariine 〉=300mg/100g finished product, polysaccharide (in glucosan) 〉=160mg/100g finished product, astragaloside and ferulic acid are all qualitative to be detected, thereby guarantees the reliability and stability of product quality.
The outward appearance of health food of the present invention is a film coating tablet, and content is a chocolate brown powder, and the special odor of this product drug component is arranged, the little sweet little hardship of its taste.
To health food sampling carrying out acute toxicity test of the present invention, sample is obeyed LD50 all greater than 10000mg/kg to the acute oral of male and female white mice, with acute toxicity median lethal dose(LD 50) toxicity grading, belongs to nontoxic level material.
Health food sample of the present invention is pink or colorless film coated tablet, and the human body recommended dose is 3.6g/60kg body weight every day.Specify the functional evaluation experiment of inspection body to show through country: (1) per os gave animal sample after 3 months, promptly had the effect that increases rat bone density, and sample can increase femur weight, femur metaphysis bone density, femur mid point bone density and calcium content.(2) the fruit bat experiment shows that the female fly of each concentration group of this sample can prolong average life 3.60-4.93 days; Biochemical indicator detects and shows, this product has the serum of reduction lipid peroxide content of degradation products, the effect of rising serum glutathione peroxidase activity.More than two experimental results show that product of the present invention has bone density improving and function in delaying senility.
Show that through stability experiment the effect duration of this product is at least two months.It is 37-40 ℃ that sample places temperature, and relative humidity is under 75% the condition, detects once continuous detecting 3 months in every month.Experimental result shows that each assay all meets the GB16740-1997 requirement.As total plate count＜10cfu/g, coliform＜30MPN/100g, mycete＜10cfu/g, yeast＜10cfu/g, pathogenic bacterium (Salmonella, shigella, staphylococcus aureus and Hemolytic streptococcus) do not detect.Lead＜0.2mg/kg, arsenic＜0.1mg/kg, hydrargyrum does not detect.
This product with Semen sojae atricolor, Herba Epimedii, the Radix Astragali, Radix Angelicae Sinensis and Fructus Mori as primary raw material, wherein Semen sojae atricolor, Herba Epimedii and the Radix Astragali not only have the activity that suppresses osteoclast, promote osteoblast, thereby the function of bone density improving, and can eliminate interior free yl, the oxidation of lipotropism matter, function with slow down aging, again with nourishing YIN and supplementing blood, the Radix Angelicae Sinensis and the Fructus Mori that include multivitamin and mineral are used together, reach the function of bone density improving and slow down aging jointly, and can not produce the adverse side effect of hormone medicine.The prescription characteristics of this product are the basic cause of disease at the human body yin and yang imbalance, from originally starting with of kidney, regulate whole machine balancing, focus on promoting the absorption of calcium in the body, mend the marrow bone strengthening, life lengthening.This with market on some products of replenishing the calcium merely compared a great difference, avoided replenishing the calcium and nonabsorbable shortcoming simply, this product has adopted full water film coating in addition, has hidden the generation of ethanol abnormal flavour, suitable health care is taken good care of food and is taken for a long time, is a kind of novel pure natural health-care.
Also have, preparation method of the present invention combines multinomial advanced technologies new technique, as Asia boil dynamic extraction, flocculation sediment, micropore fine filtration, spray drying, film-coated preparation etc., compare with the traditional preparation process method, embody advanced person, innovation, high in technological content characteristics.Adopt the Asia dynamic extraction technology of boiling, the static extract phase ratio with traditional not only makes extractive technique be further enhanced, and all improves significantly at aspects such as energy-saving and environmental protection, labor intensity and extraction time and efficient.Flocculation sediment adopts good flocculating agent chitosan, and it is dissolved in the water extract with charge neutrality and the electronegative particle of suction type sedimentation such as impurity and does not reach the polysaccharide composition, can reach purified purpose after filtration.And traditional ethanol precipitation technology length consuming time, reclaim loaded down with trivial details and to the specific (special) requirements of environment, the more and more incompatibility modern crafts requirement of producing.Flocculation sediment is also good polysaccharide active component, volatile ingredient and the various trace elements in the retained product simultaneously, and the quality of product is better guaranteed.The microporous filter technology that adopts, wherein the microporous pipe of Cai Yonging meets hygienic requirements, the aperture can be according to wanting filtering particle size to select, can wash use repeatedly, occupation area of equipment is little, and spray drying technology makes material obtain drying in moment, reduced the loss of polysaccharide active component, volatile ingredient, the quality of product is improved.Film-coated coating is a water solublity in the film-coated preparation, has advantages such as moisture-resisting, lucifuge, screening flavor, sheet type be good; Make the product tablet not easily broken, can preserve for a long time, and not contain ethanol, safer, also meet environmental protection requirement.This product has adopted multiple advanced technology, makes whole technology meet the demand of modern production, save time, laborsaving, avoid polluting, formed a modern production line.
The specific embodiment
The experiment of embodiment 1 health food bone density improving of the present invention effect
Sample character and processing: sample is pink coated tablet, label is a chocolate brown powder, the human body recommended amounts is 3.6g/60kg body weight every day, basic, normal, high three dosage groups are established in experiment: each group is respectively 0.30g, 0.60g, 1.80g/kg, is equivalent to 5 times, 10 times, 30 times of human body recommended dose.Set up three matched groups simultaneously: sham operated rats, model control group, positive controls.
Laboratory animal: the Wistar rat, female, body weight 220-250 gram.
The dosage design: sample is established basic, normal, high three dosage groups, respectively sample 0.30g, 0.60g, 1.80g is added the 10ml deionized water, presses 10ml/kg.bw every day and irritates stomach.
Experimental technique
1, oophorectomize: rat is with 30mg/kg.bw lumbar injection 1% pentobarbital sodium solution, carry out the bilateral ovaries excision after the anesthesia, the penicillin of postoperative intramuscular injection 20,000 units, for three days on end, sham operated rats is opened the fat that only excises behind the abdominal cavity about 0.5, keeps bilateral ovaries.
2, female Wistar rats is divided into basic, normal, high three the dosage groups of sham operated rats, model control group, positive controls and sample at random by body weight, every group 10, single cage is raised, sham operated rats and model control group are irritated stomach with deionized water, and the positive controls per os gives the Alendronate sodium of 1.0mg/kg.bw.Whole experimental session rat is drunk deionized water, notes down the feedstuff intake weekly, body weight, height; In animal feeding to 12 week, rat is put to death in the cervical vertebra dislocation, uses QDR-4000 type borne densitometers and measures rat femur mid point and femur metaphysis bone density, dissect rat then, peel off the left side femur, with the length of vernier caliper measurement femur, femur is dried to constant weight, and weighing is key heavy.
3, bone calcium is measured: 12398-90 measures according to standard GB.Take by weighing sample in little conical flask, add 5ml HNO
3: HCLO
4(4: 1), on add funnel, place hot digestion on the electric hot plate, as digest not exclusively, add nitric acid and continue hot digestion till the water white transparency, add the 2ml deionized water, heating is to remove unnecessary nitric acid.Take off cooling, be settled in the 100ml volumetric flask with 2% lanthana solution.Do reagent blank by aforesaid operations.
Computing formula:
C: the calcium concentration that draws on the instrument (μ g/ml)
W: samples weighing (g)
V: sample constant volume (ml)
Experimental result:
1, sample is to the influence of rat body weight
Table 2 sample is to the influence of rat body weight
| Group | Number of animals (only) | Body weight (g) | ||||
| Starting weight | January | February | March | Weightening finish (g/12 week) | ||
| Dosage group high dose group in the sham operated rats model control group positive controls low dose group | 10 10 10 10 10 10 | 232.4±6.9 231.0±14.7 233.2±6.9 230.6±9.5 235.7±8.5 229.9±5.8 | 266.7±21.6 293.0±20.2 304.2±17.5 287.9±23.1 281.9±19.6 276.1±21.6 | 283.1±34.4 316.2±23.2 329.3±27.9 308.7±19.0 307.9±19.0 301.7±19.3 | 323.3±23.0 369.2±23.5 373.2±25.8 356.5±18.7 348.0±21.3 335.8±15.1 | 90.9±25.2 138.2±26.5 140.0±26.7 125.9±22.7 112.3±26.4 105.9±16.1 |
P＜0.05 (through variance analysis).
By table 2 as seen, model control group 1,2, March body weight apparently higher than sham operated rats (P＜0.05), prompting may cause the body weight supernormal growth for animal estrogen decrease after operation causes the hormonal readiness disorder, illustrates that model sets up.Low, middle dosage group of sample and positive controls body weight and weight gain are compared no significant difference with model control group, sample high dose group body weight in March and weight gain significantly are lower than model control group.
2, sample is to the influence of rat height
Table 3 sample is to the influence of rat height
| Group | Number of animals (only) | Height (cm) | ||||
| Just long | January | February | March | Increase (cm/12 week) | ||
| Dosage group high dose group in the sham operated rats model control group positive controls low dose group | 10 10 10 10 10 10 | 21.3±0.64 21.4±0.81 21.4±1.06 21.4±0.90 21.3±0.76 21.5±0.35 | 22.3±0.79 23.1±0.68 22.4±0.79 22.5±0.90 22.7±0.86 22.9±0.49 | 23.9±0.89 24.7±0.70 24.0±0.84 24.1±0.98 24.3±0.90 24.5±0.48 | 24.3±0.90 25.2±0.72 24.4±0.85 24.5±0.99 24.8±0.91 24.9±0.49 | 3.0±0.99 3.8±0.74 3.0±0.96 3.1±0.82 3.4±0.33 3.5±0.31 |
P＜0.05 (through variance analysis).
By table 3 as seen, each is organized the height in rat each period and height and increases and all do not have significant difference.
3, the weight of rat femur, length, bone calcium and femoral bmd
Table 4 sample is to the influence of length, weight, bone calcium and the bone density of rat femur
| Group | Number of animals (only) | Femur length (cm) | Femur weight (g) | Femur metaphysis bone density (g/cm 2) | Femur mid point bone density (g/cm 2) | Calcium content of bone (mg/g) |
| Dosage group high dose group in the sham operated rats model control group positive controls low dose group | 10 10 10 10 10 10 | 3.44±0.34 3.46±0.34 3.45±0.27 3.47±0.29 3.52±0.40 3.49±0.35 | 0.68±0.071 0.59±0.052 0.67±0.058 0.65±0.060 0.68±0.057 0.69±0.064 | 0.240±0.026 0.195±0.029 0.234±0.028 0.207±0.016 0.228±0.037 0.234±0.029 | 0.227±0.007 0.189±0.020 0.221±0.029 0.207±0.035 0.218±0.027 0.224±0.021 | 270.3±38.1 180.7±55.8 237.8±40.9 223.5±40.2 254.6±35.5 273.9±309 |
P＜0.05 (through variance analysis).
By table 4 as seen, each femur length of organizing rat does not all have significant difference; Sham operated rats rat femur weight, femur metaphysis bone density, femur mid point bone density and calcium content of bone are significantly higher than model control group; Sample height, middle dosage group femur weight, femur metaphysis bone density, femur mid point bone density and calcium content of bone are significantly higher than model control group.Show that this laboratory sample has the rat bone density of increasing effect.
Embodiment 2 health foods of the present invention prolong the experiment of old and feeble effect
A, drosophila survival test
Sample: be pink coated tablet, label is a chocolate brown powder.
Experimental animal: Oregon K wild type Drosophila melanogaster (Drosophila melanogaster)
The dosage grouping: according to the human body recommended dose is (the 3.6 gram/day for human beings), establishes 1 blank group and 4 dosage groups, and the concentration that each dosage group culture medium contains sample is respectively: 0.01%, 0.04%, 0.12% and 0.36%.
Test method: collect in 8 hours the new fruit bat adult that sprouts wings, etherization is distinguished the male and female random packet down, is tested after weighing respectively.Use 400 of fruit bats, male and female half and half for every group.Matched group gives conventional corn powder culture medium; Test group contains the culture medium of 0.01%, 0.04%, 0.12% and 0.36% sample respectively.Experiment condition: 25 ± 1 ℃ of temperature, relative humidity 45～75%.Changed fresh culture once in per four days.Every day observed and recorded drosophila survival number and death toll, till the whole death of fruit bat.Calculate three indexs such as the dead natural law of half, average life and average maximum life span.
Result of the test:
Table 5 sample is to drosophila survival test statistics table
| The sex examination substrate concentration average maximum life span of number average weight half death time average life of really restricting a(d) (d) (d) for (%) (only) (mg/20 only) |
| Female 0 200 16.9 ± 0.3 54 54.64 ± 12.64 77.75 ± 4.01 0.01 200 17.2 ± 0.2 58 58.24 ± 13.41 ** 82.20±4.15 ** 0.04 200 17.0±0.4 60 59.57±12.39 ** 80.55±3.35 * 0.12 200 17.1±0.5 60 59.17±12.47 ** 78.65±2.76 0.36 200 17.0±0.3 51 51.72±14.24 77.45±2.95 |
| Male 0 200 11.7 ± 0.2 53 51.54 ± 13.09 72.05 ± 3.30 0.01 200 11.7 ± 0.2 52 50.93 ± 14.04 72.45 ± 3.19 0.04 200 11.6 ± 0.2 54 52.24 ± 13.28 73.75 ± 3.89 0.12 200 11.6 ± 0.2 51 50.37 ± 12.86 71.30 ± 3.51 0.36 200 11.6 ± 0.2 37 39.40 ± 10.14 56.75 ± 0.44 |
A is calculated by 20 fruit bats of longest-lived.
*Test group is compared the life-span prolongation with matched group, statistical test has significance (P＜0.05).
*Test group is compared the life-span prolongation with matched group, statistical test has highly significant meaning (P＜0.01).
By table 5 as seen, under this experiment condition, female fly of 0.01%, 0.04% and 0.12% concentration group and matched group are relatively seen and are prolonged average life 3.60～4.93 days; Female fly of 0.01% and 0.04% concentration group and matched group are relatively seen and are prolonged average maximum life span 4.45 and 2.80 days, the equal significance of statistical test (P＜0.05 or P＜0.01).
B, prolong old and feeble effect biochemical indicator and detect
Sample: be pink coated tablet, label is a chocolate brown powder.
32 of the male old rats of laboratory animal: SD (18 monthly age) are divided into four groups at random, 8 every group.
The dosage design: the human body recommended dose is 3.6g/60kg.bw, is basic, normal, high three dosage groups with 0.15g/kg.bw (2.5 times), 0.30g/kg.bw (5 times), 0.60g/kg.bw (10 times), and other establishes aged matched group.
Experimental technique: adopt drinking technique (sample grind after, be diluted to required dosage) with low amounts of water, feed 45d continuously, matched group gives distilled water and drinks.46d gets in the hematometry serum superoxide dismutase (SOD) vigor, glutathion peroxidase (GSH-Px) vigor in lipid peroxide catabolite malonaldehyde (MDA) content, the serum.
Experimental result
Table 6 is respectively organized rat body weight at the whole story (x ± s)
| Group | Number of animals (only) | Dosage (g/kg.bw) | Initial body weight (g) | Whole opisthosoma heavy (g) |
| Aged contrast | 8 | 0.00 | 607.5±63.71 | 668.8±93.77 |
| Low dosage | 8 | 0.15 | 605.8±86.64 | 679.8±57.31 |
| Middle dosage | 8 | 0.30 | 618.3±89.64 | 672.3±105.60 |
| High dose | 8 | 0.60 | 630.0±97.28 | 695.0±83.40 |
Table 7 is respectively organized rat blood serum MDA content, SOD, GSH-Px vitality test result (x ± S)
| Group | Number of animals (only) | MDA(nmol/ml | SOD(NU/ml) | GSH-Px(U) |
| Aged contrast | 8 | 4.78±0.24 | 410.00±32.02 | 178.95±2.29 |
| Low dosage | 8 | 4.14±0.58 * | 413.24±27.05 | 182.54±2.11 * |
| Middle dosage | 8 | 4.06±0.53 * | 434.52±21.54 | 179.64±1.87 |
| High dose | 8 | 4.82±0.27 | 416.47±11.25 | 178.54±2.64 |
*Compare p＜0.05 with aged matched group.
Experiment conclusion: show that by table 7 result low, middle dosage group serum lipid peroxide catabolite malonaldehyde (MDA) content is starkly lower than matched group (P＜0.05), low dose group serum glutathion peroxidase (GSH-Px) vigor apparently higher than matched group (P＜0.05), show that this sample has certain reduction lipid peroxidation and has rising GSH-Px effect.
The preparation of embodiment 3 health foods of the present invention
1, take by weighing Radix Angelicae Sinensis crude drug 250 gram, carry out mechanical activation comminution after, 20 orders that sieve, the powder that obtains adopts supercritical CO
2Extraction process is extracted, and powder is put into supercritical CO
2Extraction pot, extraction pressure is 10Mpa, and extracting temperature is 40 ℃, separates to such an extent that Radix Angelicae Sinensis oil 0.75 restrains then in knockout drum, and standby, separating pressure is 1Mpa, and separation temperature is 20 ℃, liquid CO
2Flow is 25Nm
3/ h recycles on stream and extracts, and extraction time is 2 hours, takes out Radix Angelicae Sinensis powder 249 grams carry behind the oil from extraction pot, and is standby;
2, take by weighing Semen sojae atricolor 1kg, carry out mechanical activation comminution after, 20 orders that sieve, the powdered soybean that obtains with defat with n-hexane after, drying is removed and to be desolvated.Use 80% ethanol extraction, extracting solution concentrates in 60 ℃, again by 90-95% ethanol Chong Knot crystalline substance, drying, purity be 40% soybean isoflavone, standby;
3, take by weighing Herba Epimedii 500 grams, the Radix Astragali 500 grams and Fructus Mori 250 grams, with above-mentioned standby Radix Angelicae Sinensis powder 249 grams of carrying behind the oil, water with 10 times (weight ratios) extracts, be heated to the 95-98 ℃ of Asia state that boils, dynamic circulation water extraction 1 hour, extracting solution filters with 60 mesh filter screens, and filtrate is concentrated into relative density and reaches 1.03-1.04 (60-65 ℃) under 65 ℃ and vacuum 0.08MPa.Add the chitosan that concentration is 200ppm again, flocculation sediment half an hour, with 200 order micropore fine filtrations, fine straining liquid is concentrated into the concentrated solution relative density and reaches 1.08-1.10 (60-65 ℃) under 65 ℃ and vacuum 0.08Mpa with flocculation sediment liquid, with gained concentrated solution spray drying, get spray powder;
4, the gained spray powder is fully mixed with the above-mentioned Radix Angelicae Sinensis oil and the soybean isoflavone that obtain of extracting respectively, get mixed powder, add calcium gluconate 20 grams again, carboxymethyl starch sodium 15 grams, microcrystalline Cellulose 15 grams, stir mixed, 80 orders that sieve are granulated, and adopt pasteurization, material after granulation hot blast (60 ± 5 ℃) continuous drying 4 hours in baking oven, granule 180 grams;
5, with the granule tabletting, pink film coating, 200 in the tablet of getting product, every contains 0.9g gram dosage.
Instructions about how to take medicine: obey each 2 (adult's recommended dose is 3.6g/60kg days) every day 2 times.
Claims (4)
1, the manufacture method of a kind of bone density improving and anti-aging health food is characterized in that raw materials used component and content are as follows:
Component Semen sojae atricolor Herba Epimedii astragalus, angelica Fructus Mori calcium gluconate carboxymethyl starch sodium microcrystalline Cellulose
Weight portion 10-40 3-10 3-10 3-10 1-10 0.3-3 0.1-3 0.1-3
Described manufacture method comprises the following steps:
(1) take by weighing Radix Angelicae Sinensis, pulverize, 20 orders that sieve adopt supercritical CO
2Extraction process is extracted: extraction pot pressure is 5-20MPa, and temperature is 20-60 ℃; Knockout drum pressure is 1-1.5MPa, and separation temperature is 15-20 ℃; Liquid CO
2Flow is 20-40Nm
3/ h, extraction time is 1-3 hour, the Radix Angelicae Sinensis powder after extraction separation gets Radix Angelicae Sinensis oil and carries oil;
(2) take by weighing Semen sojae atricolor, pulverize, 20 orders that sieve, ethanol extraction use in defat, and extracting solution concentrates in 60-80 ℃, and refining by 90-95% ethanol again, drying gets soybean isoflavone;
(3) take by weighing Herba Epimedii, the Radix Astragali and Fructus Mori, with the described Radix Angelicae Sinensis powder of carrying behind the oil, water with 10-12 times (weight ratio) extracts, be heated to the 95-98 ℃ of Asia state that boils, dynamic circulation water extraction 1-3 hour, extracting solution filters with 60 mesh filter screens, filtrate is vacuum concentration under 50-80 ℃ and vacuum 0.04-0.09MPa, assign 1.03-1.04 at 60-65 ℃ to relative density, the reuse chitosan is refining, 200 order micropore fine filtrations, and gained fine straining liquid vacuum concentration to concentrated solution relative density is assigned 1.08-1.10 at 60-65 ℃, with gained concentrated solution spray drying, get spray powder;
(4) spray powder is mixed with described Radix Angelicae Sinensis oil and soybean isoflavone, add calcium gluconate again, carboxymethyl starch sodium and microcrystalline Cellulose, mixed, 80 orders that sieve are granulated, and drying gets granule;
(5) with the granule tabletting, film coating, tablet gets product.
2, the manufacture method of health food as claimed in claim 1 is characterized in that raw materials used component and content are
Component Semen sojae atricolor Herba Epimedii astragalus, angelica Fructus Mori calcium gluconate carboxymethyl starch sodium microcrystalline Cellulose
Weight portion 20 10 10 55 0.4 0.3 0.3
3, the health food that comes out of the manufacture method manufacturing of health food as claimed in claim 1.
4, the health food that comes out of the manufacture method manufacturing of health food as claimed in claim 2.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021511470A CN1176602C (en) | 2002-12-06 | 2002-12-06 | Health food capable of increasing bone density and delaying senility and its production process |
| PCT/CN2003/001017 WO2004052120A1 (en) | 2002-12-06 | 2003-11-28 | A healthy food for increasing bone density and anti-aging |
| AU2003289630A AU2003289630A1 (en) | 2002-12-06 | 2003-11-28 | A healthy food for increasing bone density and anti-aging |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021511470A CN1176602C (en) | 2002-12-06 | 2002-12-06 | Health food capable of increasing bone density and delaying senility and its production process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1416728A CN1416728A (en) | 2003-05-14 |
| CN1176602C true CN1176602C (en) | 2004-11-24 |
Family
ID=4751933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021511470A Expired - Lifetime CN1176602C (en) | 2002-12-06 | 2002-12-06 | Health food capable of increasing bone density and delaying senility and its production process |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN1176602C (en) |
| AU (1) | AU2003289630A1 (en) |
| WO (1) | WO2004052120A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100367952C (en) * | 2003-09-30 | 2008-02-13 | 戴向国 | Calcium L-Threonate and soy bean isoflavone containing combination |
| CN1293870C (en) * | 2003-12-26 | 2007-01-10 | 吴英萍 | Medicine for treating osteoporosis and its preparing method |
| CN100441555C (en) * | 2004-04-09 | 2008-12-10 | 汪云 | Composition containing resveratrol and soybean isoflavone and its preparation and use |
| CN100356914C (en) * | 2005-11-25 | 2007-12-26 | 上海大学 | Method for preparing soybean isoflavone tablet |
| CN100356869C (en) * | 2005-12-27 | 2007-12-26 | 武汉哈福科技有限公司 | Health-care food with functions of anti-senium and cosmetic |
| CN101139378B (en) * | 2007-10-24 | 2010-12-15 | 中国农业大学 | Method for extracting calycosin-7-O-beta-D-glucoside from astragalus root |
| CN102144677A (en) * | 2011-04-06 | 2011-08-10 | 中国药文化研究会 | Angelica sinensis health care oil, preparation method and application of angelica sinensis health care oil |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1096204A (en) * | 1993-06-12 | 1994-12-14 | 李延明 | Anti-constitutional drinking medicine for primary osteoporosis and processing method thereof |
| CN1038813C (en) * | 1993-07-02 | 1998-06-24 | 周勇 | Traditional Chinese medicine for curing osteoporosis |
| CN1256921A (en) * | 1998-12-17 | 2000-06-21 | 西安医科大学第一临床医学院 | Anti-senility medicine for preventing and treating senile osteoporosis |
| CN1141092C (en) * | 2001-01-19 | 2004-03-10 | 郭兴华 | Composition for preventing and treating osteoporosis and cancer and decreasing blood fat and its application |
-
2002
- 2002-12-06 CN CNB021511470A patent/CN1176602C/en not_active Expired - Lifetime
-
2003
- 2003-11-28 WO PCT/CN2003/001017 patent/WO2004052120A1/en not_active Application Discontinuation
- 2003-11-28 AU AU2003289630A patent/AU2003289630A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004052120A1 (en) | 2004-06-24 |
| CN1416728A (en) | 2003-05-14 |
| AU2003289630A1 (en) | 2004-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108850366A (en) | A kind of alternative tea composition and preparation method thereof with anti-trioxypurine effect | |
| CN110200276A (en) | Composition and the application for being used to treat diabetes based on Chinese medicine nutrition treatment | |
| CN105176772A (en) | Tartary buckwheat base liquor, tartary buckwheat liquor and production methods thereof | |
| CN101966222A (en) | Medicinal composition and preparation for strengthening bones and preparation method thereof | |
| CN106072626B (en) | It is a kind of towards doctor's compound antler health-care food and its preparation method and application | |
| CN1176602C (en) | Health food capable of increasing bone density and delaying senility and its production process | |
| CN1864530A (en) | A refined health food of high and cold mountain area crop and processing technology thereof | |
| CN104758556B (en) | A kind of compound preparation and preparation method thereof of anti-Heat stress | |
| CN100345566C (en) | Medicine composition used for reducing weight, prepn. method and use thereof | |
| CN107581607A (en) | A kind of health food for improving sleep and preparation method thereof | |
| CN109876135B (en) | Eucommia ulmoides leaf and corn peptide composition capable of reducing blood pressure and blood fat and preparation method thereof | |
| CN101036722A (en) | Health-caring food for easing and improving climacteric Syndrome of men and the preparation thereof | |
| CN1840092A (en) | 'Mo Luo' granule for treating atrophic gastritis and preparation method thereof | |
| CN113499366B (en) | Composition with function of reducing blood sugar and blood fat simultaneously and preparation method thereof | |
| CN1231255C (en) | Capsule formula for treating astriction prepared using pumpkin as main raw material and its preparation method | |
| WO2021179482A1 (en) | Traditional chinese medicine compound composition having effect of promoting bone health as well as preparation method therefor and application thereof | |
| CN100340266C (en) | Jiangzhi capsule good for liver and its preparing process | |
| CN1283269C (en) | Compound preparation of forest frog, and preparation method | |
| CN113209217A (en) | Traditional Chinese medicine composition for resisting physical fatigue and preparation method thereof | |
| CN1070827A (en) | Up-to-date therapeutic agent of diabetes and method for making thereof | |
| CN108552525B (en) | Lipid-lowering weight-losing functional food | |
| CN1232274C (en) | Composite medicine for prevention and cure of osteoporosis and its application | |
| CN1199683C (en) | Medicine combination for reducing blood fat and preventing senescence and its medicines | |
| CN1284482C (en) | Nutritious food with immunity-regulating, blood sugar-decreasing functions and its manufacturing method | |
| CN1290566C (en) | Depression treating medicinal formulation and its preparation process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: SHANGHAI MODERN TCM CO., LTD. Free format text: FORMER NAME: SHANGHAI MODERN CHINESE TRADITIONAL MEDICINE TECHNOLOGY DEVELOPMENT CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: Shanghai city 200051 Days Road Lane 600 Civic Plaza East 7F-C Patentee after: Shanghai Sundise Chinese Medicine Technology Development Co.,Ltd. Address before: Shanghai city 200051 Days Road Lane 600 Civic Plaza East 7F-C Patentee before: Shanghai Sundise |
|
| CX01 | Expiry of patent term |
Granted publication date: 20041124 |
|
| CX01 | Expiry of patent term |